Singapore markets closed

Straits Times Index
3,296.89
+4.20(+0.13%)
S&P 500
5,044.44
+26.05(+0.52%)
Dow
38,125.45
+222.16(+0.59%)
Nasdaq
15,743.37
+137.88(+0.88%)
Bitcoin USD
59,152.48
+1,898.57(+3.32%)
CMC Crypto 200
1,273.11
+2.37(+0.19%)

REGN Jun 2024 430.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

484.05

0.00

(0.00%)

As of 09:49AM EDT. Market open.

GuruFocus.com
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...
First Quarter Results Show Revenue Decline but Strong Dupixent and Libtayo Sales Growth
Simply Wall St.
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...
GlobeNewswire
Regeneron Reports First Quarter 2024 Financial and Operating Results
First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP dil